Back to Journals » Drug, Healthcare and Patient Safety » Volume 4

Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy

Authors Ciliberto M, Weisenberg J, Wong M

Received 1 June 2012

Accepted for publication 25 June 2012

Published 26 July 2012 Volume 2012:4 Pages 81—86

DOI https://doi.org/10.2147/DHPS.S28814

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Michael A Ciliberto, Judith LZ Weisenberg, Michael Wong

Department of Neurology, Washington University School of Medicine, St Louis, MO, USA

Abstract: One-third of patients with epilepsy continue to have seizures despite current treatments, indicating the need for better antiseizure medications with novel mechanisms of action. Ezogabine (retigabine) has recently been approved for adjunctive treatment of partial-onset seizures in adult patients with epilepsy. Ezogabine utilizes a novel mechanism of action, involving activation of specific potassium channels. The most common side effects of ezogabine are shared by most antiseizure medications and primarily consist of central nervous system (CNS) symptoms, such as somnolence, dizziness, confusion, and fatigue. In addition, a small percentage of patients on ezogabine experience a unique adverse effect affecting the bladder, which results in urinary hesitancy; thus, patients on ezogabine should be monitored carefully for potential urological symptoms. Overall, ezogabine appears to be well tolerated and represents a reasonable new option for treating patients with intractable epilepsy.

Keywords: antiepileptic drug, seizure, bladder, potassium channels

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]